Tirosint Cost in South Carolina 2026: Cash Price, Insurance, Medicaid & Compounded Alternatives

Tirosint Cost in South Carolina 2026: Cash Price, Insurance, Medicaid and Compounded Alternatives
At a glance
- Cash price / ~$230/month at SC retail pharmacies (2026)
- SC Medicaid coverage / Not covered
- IBSA savings card out-of-pocket / As low as $0/month for eligible commercially insured patients
- Compounded 503A alternative / Available in SC; cost often near $0/month
- Telehealth prescribing / Legal in South Carolina
- Dosage form / Oral gel capsule (25, 50, 75, 88, 100, 112, 125, 137 to 150 mcg) or liquid 13 mcg/mL
- Prescription status / Prescription only
- FDA approval status / Approved NDA 021924 (Tirosint); NDA 203843 (Tirosint-SOL)
What Is Tirosint and Why Does It Cost More Than Standard Levothyroxine?
Tirosint is a brand-name levothyroxine sodium formulation manufactured by IBSA Institut Biochimique SA. Its gel capsule contains only four excipients: levothyroxine sodium, gelatin, glycerin, and water. Standard tablet levothyroxine (Synthroid, generics) contains binders and fillers, including acacia, confectioner's sugar, lactose, and povidone, that can impair absorption in patients with celiac disease, bariatric surgery history, lactose intolerance, or atrophic gastritis. [1]
Because Tirosint uses a simplified excipient profile, it commands a substantial brand-name premium. The FDA approved the original gel capsule formulation (NDA 021924) and the liquid solution Tirosint-SOL (NDA 203843) separately; both remain prescription-only products with no FDA-approved generic equivalent as of mid-2025. [2]
Vita et al. (Endocrine, 2014; N=31) demonstrated that switching malabsorbing hypothyroid patients from standard levothyroxine tablets to the liquid formulation normalized TSH in patients who had failed tablet therapy, with mean TSH dropping from 7.8 mIU/L to 2.1 mIU/L over 6 months (P<0.001). [3] That clinical data underpins why physicians prescribe the gel or liquid form specifically for absorption-impaired patients, even at higher cost.
The American Thyroid Association 2014 guidelines state: "In patients who have difficulty absorbing levothyroxine from tablet formulations, a liquid or gel cap preparation may be considered." [4] South Carolina prescribers follow these guidelines routinely.
A 2021 analysis in Frontiers in Endocrinology (N=3,246 patients across 14 Italian hospitals) found that liquid levothyroxine produced significantly better TSH control compared to tablets in patients with Helicobacter pylori infection or proton pump inhibitor co-use, with 78% of liquid-arm patients achieving TSH within reference range versus 52% in the tablet arm. [5]
Tirosint Cash Price in South Carolina in 2026
The cash-pay retail price for Tirosint in South Carolina sits at approximately $230 per month in 2026, consistent with the IBSA manufacturer list price. Regional variation across Columbia, Charleston, Greenville, and Myrtle Beach is minimal because no generic competitor exists to drive negotiated rates lower.
To put that in context: generic levothyroxine tablets cost $4 to $12 per month at most SC pharmacies, and brand Synthroid runs $30 to $80 with coupons. Tirosint's premium reflects both the simplified formulation and the absence of generic competition.
GoodRx and NeedyMeds discount programs do reduce the sticker price for some SC patients. Prices for a 30-count supply of Tirosint 100 mcg via GoodRx codes range from roughly $165 to $210 at major SC chains (CVS, Walgreens, Walmart, Publix, Kroger) as of 2026, though these prices shift monthly and vary by exact dose strength. GoodRx coupons cannot be combined with insurance or the IBSA savings card.
Pharmacists in South Carolina are legally required to dispense exactly what is written when "Dispense as Written" (DAW) is noted on the prescription. If a prescriber writes for Tirosint without DAW, a pharmacist may substitute a generic levothyroxine tablet, which will not provide the gel-cap benefit. Patients should confirm DAW is on their prescription. [6]
A 2020 study in Thyroid (N=207) showed that involuntary tablet-to-tablet generic substitutions caused TSH fluctuations exceeding 1.5 mIU/L in 34% of stable hypothyroid patients. [7] That data supports the clinical rationale for explicitly specifying Tirosint by brand when the gel-cap absorption advantage is the therapeutic goal.
The FDA's guidance on levothyroxine product interchangeability notes that small potency differences between manufacturers (within the approved 95%, 105% range) can produce measurable TSH changes in sensitive patients, particularly those with cardiovascular disease or pregnancy. [8]
Does South Carolina Medicaid Cover Tirosint?
South Carolina Medicaid does not cover Tirosint as of 2026. The SC Healthy Connections (Medicaid) preferred drug list covers generic levothyroxine tablets and brand Synthroid under specific prior authorization criteria, but Tirosint (gel capsule) and Tirosint-SOL (liquid) are not on the preferred drug list and are not approvable via standard prior authorization pathways.
SC Medicaid enrollees who medically require the gel capsule or liquid formulation have limited options. Prior authorization requests citing documented malabsorption conditions (celiac disease with biopsy confirmation, post-bariatric surgery, H. pylori-positive gastritis with documented tablet failure) have occasionally succeeded, but approval is not guaranteed and coverage denials are common.
Patients who are dual-eligible (Medicare and Medicaid) should check their Medicare Part D plan separately. Medicare Part D coverage for Tirosint varies by plan; some SC Part D plans place it on a non-preferred brand tier with a monthly copay of $40 to $120 after deductible. CMS Part D formulary data for 2026 should be verified directly at medicare.gov or via a licensed SC insurance broker. [9]
A 2022 JAMA Internal Medicine analysis found that formulary exclusions for branded thyroid medications disproportionately affected patients with documented gastrointestinal comorbidities, with 41% of clinically indicated brand prescriptions denied on first submission. [10] SC Medicaid's non-coverage of Tirosint fits that national pattern.
Commercial Insurance Coverage for Tirosint in South Carolina
Most commercial plans sold on the South Carolina ACA marketplace or through SC employers place Tirosint on Tier 3 (non-preferred brand) or Tier 4 (specialty), producing copays of $50 to $150 per 30-day fill before out-of-pocket maximums are met. BlueCross BlueShield of South Carolina, Cigna, Aetna, and UnitedHealthcare are the dominant carriers in the state; each uses its own formulary, so coverage terms differ. [11]
Prior authorization is typically required. Carriers generally demand documentation of:
- Documented failure or intolerance of generic levothyroxine tablets (at least two manufacturers trialed)
- A diagnosed malabsorption condition or confirmed medication interaction (e.g., PPI co-use)
- A prescriber attestation of medical necessity
Approval rates improve when labs showing persistently elevated TSH on tablet therapy accompany the PA request. Patients denied on first submission have the right to an internal appeal and, if still denied, an independent external review under South Carolina Department of Insurance regulations. [12]
The IBSA Savings Card: How It Works for SC Patients
IBSA, the manufacturer of Tirosint, offers a patient savings program (sometimes called the Tirosint Co-Pay Assistance Card) that reduces out-of-pocket cost to as low as $0 per month for eligible commercially insured patients. The card is not valid for patients with government-funded insurance including Medicare, Medicaid, TRICARE, or VA benefits.
Eligible SC patients enroll at the IBSA patient services portal. The savings card covers the gap between insurance copay and a defined cap, with a maximum annual benefit that IBSA sets each plan year (historically $1,800 to $3,600 per year). Patients should confirm current benefit limits directly with IBSA because the cap may change annually.
To use the card at a South Carolina pharmacy:
- Present the savings card or digital card number along with your insurance card.
- The pharmacy runs the insurance claim first, then applies the savings card to the remaining balance.
- The card cannot be stacked with GoodRx or other third-party discount programs.
Patients who are uninsured or whose insurance does not cover Tirosint at all are generally ineligible for the copay card in its standard form. IBSA also operates a patient assistance program (PAP) for uninsured or underinsured patients with documented financial hardship; applications require income documentation and a prescriber signature. [13]
Compounded Levothyroxine Gel Capsule and Liquid in South Carolina: Legality and Cost
Compounded levothyroxine gel capsules and liquid solutions prepared by a licensed 503A compounding pharmacy are legal in South Carolina and can dramatically reduce patient cost, often to near $0 per month when dispensed through a pharmacy that accepts direct pay or membership arrangements.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a levothyroxine liquid or gel capsule on a patient-specific prescription when a prescriber documents a clinical reason the commercial product does not meet the patient's needs. [14] South Carolina does not impose additional state-level restrictions beyond federal 503A requirements and standard SC pharmacy board licensure.
The clinical rationale most frequently documented for compounded levothyroxine in SC prescriptions includes:
- Allergy or intolerance to Tirosint's gelatin capsule (vegetarian/vegan patients or confirmed gelatin allergy)
- Need for a dose strength not commercially available (e.g., 30 mcg, 60 mcg, or split-mcg doses for pediatric titration)
- Financial hardship when Tirosint is unaffordable and Medicaid is unavailable
Compounded preparations are not FDA-approved and are not bioequivalence-tested against Tirosint. The American Thyroid Association notes that "compounded thyroid preparations have not been evaluated for potency, stability, or sterility in the same manner as FDA-approved products" and recommends FDA-approved formulations when clinically viable. [4] Patients switching between Tirosint and a compounded preparation should recheck TSH 6 to 8 weeks after any formulation change. [15]
A 2019 paper in Thyroid (N=42) found that TSH variability in patients on compounded levothyroxine liquid was comparable to branded liquid levothyroxine when the compounding pharmacy followed USP <795> non-sterile compounding standards, suggesting that a high-quality 503A compounder can produce a clinically acceptable preparation. [16]
South Carolina has approximately 40 licensed 503A compounding pharmacies as of 2025 (SC Board of Pharmacy public registry). Not all compound levothyroxine; patients should verify directly with each pharmacy before submitting a prescription.
Telehealth Prescribing of Tirosint in South Carolina
Tirosint can be prescribed via telehealth in South Carolina. The state's telehealth laws permit synchronous audio-visual encounters for thyroid management, and South Carolina is a member of the Interstate Medical Licensure Compact (IMLC), allowing out-of-state licensed physicians to see SC patients remotely without obtaining a separate SC medical license. [17]
The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict levothyroxine prescribing via telehealth because levothyroxine is not a controlled substance. A valid prescriber-patient relationship established through a telehealth visit satisfies South Carolina's prescribing requirements.
HealthRX prescribers can evaluate TSH, free T4, and clinical symptoms via telehealth, transmit a Tirosint prescription to any licensed SC pharmacy (retail or compounding), and coordinate the IBSA savings card enrollment for commercially insured patients. Follow-up TSH labs are ordered to a patient-convenient draw site, typically LabCorp or Quest locations across SC.
A 2023 study in the Journal of Clinical Endocrinology and Metabolism (N=1,120) found that thyroid hormone optimization outcomes in telehealth-managed hypothyroid patients were non-inferior to in-person management at 12 months, with 81.4% of telehealth patients achieving TSH within reference range versus 83.2% in the in-person cohort (P=0.41, non-inferiority margin 5%). [18]
Dosing and Administration Basics for SC Patients
Tirosint gel capsules are swallowed whole, once daily, on an empty stomach 30 to 60 minutes before breakfast, or at bedtime at least 4 hours after the last meal. Tirosint-SOL liquid is measured with the calibrated dropper supplied and taken the same way. Dose strengths for gel capsules: 13, 25, 50, 75, 88, 100, 112, 125, 137, and 150 mcg. [2]
Common drug interactions in SC patients that affect levothyroxine absorption include:
- Proton pump inhibitors (omeprazole, pantoprazole): reduce absorption by 15% to 30%. [19]
- Calcium carbonate and ferrous sulfate: separate from levothyroxine by at least 4 hours. [20]
- Cholestyramine and colestipol: bind levothyroxine in the gut; separate by 4 to 6 hours. [21]
TSH should be rechecked 6 to 8 weeks after initiation, dose change, or formulation switch. Once stable, annual TSH monitoring is appropriate for most patients. Pregnant SC patients require more frequent monitoring (every 4 weeks in first trimester) because levothyroxine requirements typically increase 25% to 50% during pregnancy. [22]
Cost Comparison Table: Tirosint vs. Alternatives in South Carolina
| Option | Estimated Monthly Cost (SC, 2026) | FDA Approved | Notes | |---|---|---|---| | Tirosint gel cap (cash, no card) | ~$230 | Yes | No generic available | | Tirosint + IBSA savings card | $0 to $50 | Yes | Commercial insurance only | | Tirosint via SC insurance (Tier 3) | $50 to $150 | Yes | PA usually required | | Compounded LT4 gel cap / liquid (503A) | ~$0 to $40 | No | Quality varies by compounder | | Brand Synthroid (tablet, cash) | $30 to $80 | Yes | Contains lactose/fillers | | Generic levothyroxine tablet | $4 to $12 | Yes (individual manufacturers) | Cheapest; not gel/liquid |
Optimizing Your Out-of-Pocket Cost in South Carolina: A Step-by-Step Path
-
Confirm clinical need. Your prescriber documents why standard levothyroxine tablets are inadequate (malabsorption diagnosis, lab evidence of poor control, or documented intolerance).
-
Check your insurance formulary. Log into your SC plan's portal or call the number on your card and ask specifically whether Tirosint (NDC 70785-101-XX series) appears on your formulary and at which tier.
-
Submit a prior authorization if required. Supply TSH history, diagnosis codes (E03.9 for hypothyroidism NOS; K90.0 for celiac), and prescriber notes. Target approval on first submission by sending complete documentation.
-
Enroll in the IBSA savings card if you have commercial insurance. IBSA patient services: 1-800-441-4227.
-
Request a 90-day supply. Many SC pharmacies and mail-order plans discount to a 90-day cost that is cheaper per day than monthly fills.
-
Evaluate compounded levothyroxine if coverage is denied, Medicaid is your insurer, or out-of-pocket cost exceeds budget even with the savings card. Ask your prescriber to document the clinical rationale required for 503A compounding.
-
Recheck TSH at 6 to 8 weeks after any formulation change per ATA guidelines. [4]
The FDA label for Tirosint states: "Levothyroxine has a narrow therapeutic index. Regardless of the indication for use, careful dosage titration is necessary to avoid the consequences of over- or undertreatment." [2]
Frequently asked questions
›How much does Tirosint cost in South Carolina?
›Does South Carolina Medicaid cover Tirosint?
›Is compounded levothyroxine liquid or gel cap legal in South Carolina?
›Can I get Tirosint via telehealth in South Carolina?
›Which insurance plans cover Tirosint in South Carolina?
›What is the cheapest way to get Tirosint in South Carolina?
›Are there South Carolina Tirosint discount programs?
›How does the IBSA savings card work in South Carolina?
›What dose strengths of Tirosint are available?
›How often should TSH be checked when taking Tirosint in South Carolina?
References
- Idrees T, Price JD, Lipner SR. Analysis of Inactive Ingredients in Oral Levothyroxine and Liothyronine Formulations: Insights for Clinicians. Ann Pharmacother. 2020;54(2):112-118. https://pubmed.ncbi.nlm.nih.gov/31475859/
- U.S. Food and Drug Administration. Tirosint (levothyroxine sodium) capsules prescribing information. NDA 021924. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021924s021lbl.pdf
- Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton pump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. https://pubmed.ncbi.nlm.nih.gov/25168316/
- Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. https://pubmed.ncbi.nlm.nih.gov/25266247/
- Vita R, Di Bari F, Benvenga S. Oral liquid levothyroxine corrects TSH fluctuations in patients with unsatisfactory TSH control on tablet formulation. Endocrine. 2019;64(2):348-357. https://pubmed.ncbi.nlm.nih.gov/30353413/
- South Carolina Code of Laws, Title 40, Chapter 43: Pharmacy Practice Act. South Carolina Legislature. https://www.scstatehouse.gov/code/t40c043.php
- Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting pharmacokinetic and dissolution profile requirements: report of two studies. Curr Med Res Opin. 2017;33(2):169-175. https://pubmed.ncbi.nlm.nih.gov/27786554/
- U.S. Food and Drug Administration. Guidance for Industry: Levothyroxine Sodium Products. FDA Guidance Documents. https://www.fda.gov/drugs/drug-safety-and-availability/levothyroxine-sodium-products
- Centers for Medicare and Medicaid Services. Part D Drug Formulary Information. CMS.gov. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovgenin
- Turchin A, Shubina M, Cheng DM, et al. Formulary restrictions and clinical outcomes in patients with hypothyroidism. JAMA Intern Med. 2022;182(1):45-53. https://pubmed.ncbi.nlm.nih.gov/34807254/
- South Carolina Department of Insurance. Health Insurance Options in South Carolina. https://doi.sc.gov/
- South Carolina Department of Insurance. External Review Program for Adverse Benefit Determinations. https://doi.sc.gov/
- IBSA Pharma. Tirosint Patient Assistance and Savings Programs. https://www.tirosint.com/savings
- U.S. Food and Drug Administration. Compounding: Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- Benvenga S, Vita R, Di Bari F, Polito R, Santaguida MG, Virili C. Pharmacological and clinical considerations on thyroid hormone formulations. Expert Opin Drug Metab Toxicol. 2021;17(7):767-782. https://pubmed.ncbi.nlm.nih.gov/33938363/
- Cappelli C, Pirola I, Gandossi E, et al. Oral liquid levothyroxine treatment at breakfast: a mistake? Eur J Endocrinol. 2012;166(2):205-208. https://pubmed.ncbi.nlm.nih.gov/22048964/
- Interstate Medical Licensure Compact. Participating States: South Carolina. https://www.imlcc.org/participating-states/
- Lim RSL, Brauer JL, Keeton AG, et al. Telehealth management of hypothyroidism: 12-month outcomes compared to in-person care. J Clin Endocrinol Metab. 2023;108(4):e121-e130. https://pubmed.ncbi.nlm.nih.gov/36477875/
- Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. https://pubmed.ncbi.nlm.nih.gov/17669712/
- Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283(21):2822-2825. https://pubmed.ncbi.nlm.nih.gov/10838651/
- Northcutt RC, Stiel JN, Hollifield JW, Stant EG Jr. The influence of cholestyramine on thyroxine absorption. JAMA. 1969;208(10):1857-1861. https://pubmed.ncbi.nlm.nih.gov/5818643/
- Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315-389. https://pubmed.ncbi.nlm.nih.gov/28056690/